Company CVAbout JFL Life Sciences Ltd 
JFL Life Sciences Ltd
Micro Cap
Pharmaceuticals & Biotechnology
JFL Life Sciences Limited was incorporated as `JFL Life Sciences Private Limited' on April 25, 2010 as a Private Limited Company. Pursuant to a Special Resolution held on February 10, 2022, Company converted from a Private Limited to Public Limited Company and name of the Company was changed to `JFL Life Sciences Limited', on March 3, 2022. The Company manufactures and market pharmaceutical products.
Company Coordinates
No Company Details Available
Capital StructureCapital Structure
Present Equity Capital
INR 33.00 Cr
Number of Shares
3.3 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
24-Sep-2024
3.3
33.00
21996882
10
Bonus Issue
07-Sep-2022
1.1
11.00
2978000
10
Public Issue
13-Jan-2022
80.2
8.02
7402484
10
Bonus Issue
06-Jan-2021
6.18
0.62
120000
10
Private Placement
21-Oct-2020
4.98
0.50
33721
10
Right Issues
15-Jul-2020
4.64
0.46
40309
10
Right Issues
20-Mar-2019
4.24
0.42
18732
10
Right Issues
03-Jul-2018
4.05
0.41
27272
10
Right Issues
30-Apr-2018
3.78
0.38
17897
10
Right Issues
09-Feb-2018
3.6
0.36
47607
10
Right Issues
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
Smiral Ashwinkumar Patel (44.33%)
Highest Public shareholder
Pratik Rajendra Gandhi (1.22%)
Individual Investors Holdings
28.88%
Board of Directors
Management
Designation
Remuneration
Smiral Ashwinkumar Patel
Managing Director
0
Manishkumar Jasvantlal Patel
Chairman & Non Executive Dir.
0
Tejal Smiral Patel
Whole-time Director
0
Sonu Lalitkumar Jain
Non-Exec. & Independent Dir.
0
Bhavna Shah
Non-Exec. & Independent Dir.
0
Pratima Singh
Company Secretary
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Cost of Materials Consumed
66.7744
0%
Cost of Materials Consumed
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
30 Cr
(Quarterly Results - Sep 2025)
Net Profit:
2 Cr
Pharmaceuticals & Biotechnology
INR Cr (Micro Cap)
9.00
NA
0.00%
0.00
0.00%
0.00
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
